Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

<strong>Background</strong> Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formatio...

Full description

Bibliographic Details
Main Authors:	Höglander, EK, Nord, S, Wedge, DC, Lingjærde, OC, Silwal-Pandit, L, Gythfeldt, HV, Vollan, HKM, Fleischer, T, Krohn, M, Schlitchting, E, Borgen, E, Garred, Ø, Holmen, MM, Wist, E, Naume, B, Van Loo, P, Børresen-Dale, A-L, Engebraaten, O, Kristensen, V
Format:	Journal article
Language:	English
Published:	BioMed Central 2018

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

Similar Items